| Literature DB >> 28079176 |
Duan Wang1, Yang Yang2, Qi Li1, Shen-Li Tang3, Wei-Nan Zeng4, Jin Xu5, Tian-Hang Xie1, Fu-Xing Pei1, Liu Yang4, Ling-Li Li1, Zong-Ke Zhou1.
Abstract
Femoral nerve blocks (FNB) can provide effective pain relief but result in quadriceps weakness with increased risk of falls following total knee arthroplasty (TKA). Adductor canal block (ACB) is a relatively new alternative providing pure sensory blockade with minimal effect on quadriceps strength. The meta-analysis was designed to evaluate whether ACB exhibited better outcomes with respect to quadriceps strength, pain control, ambulation ability, and complications. PubMed, Embase, Web of Science, Wan Fang, China National Knowledge Internet (CNKI) and the Cochrane Database were searched for RCTs comparing ACB with FNB after TKAs. Of 309 citations identified by our search strategy, 12 RCTs met the inclusion criteria. Compared to FNB, quadriceps maximum voluntary isometric contraction (MVIC) was significantly higher for ACB, which was consistent with the results regarding quadriceps strength assessed with manual muscle strength scale. Moreover, ACB had significantly higher risk of falling versus FNB. At any follow-up time, ACB was not inferior to FNB regarding pain control or opioid consumption, and showed better range of motion in comparison with FNB. ACB is superior to the FNB regarding sparing of quadriceps strength and faster knee function recovery. It provides pain relief and opioid consumption comparable to FNB and is associated with decreased risk of falls.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28079176 PMCID: PMC5228345 DOI: 10.1038/srep40721
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Details of meta-analyses published on this subject.
| Author | Year | Studies included | Patients (knees) | Evidence | Indicators | Conclusions |
|---|---|---|---|---|---|---|
| Dong | 2016 | 6 RCTs and 2 n-RCTs | 751 (751) | Level III | A, B, C, D, E, G | ACB shows no superiority than FNB group. Both of them can reduce the pain score after TKA |
| Li | 2015 | 8 RCTs | 434 (504) | Level II | A, B, C, D, F, G, H | ACB provide better ambulation ability, faster recovery and better pain control at rest after TKA compared to FNB |
| Kuang | 2015 | 4 RCTs and 3 CCTs | 828 (828) | Level III | A, B, C, D, E, F, H | ACB results in fast pain relief and early ambulation while decreasing post-operative nausea |
| Li | 2015 | 7 RCTs and 2 n-RCTs | 639 (639) | Level III | A, B, C, D, E, F | ACB preserved the strength of quadriceps more than FNB and achieves similar analgesic effects in postoperative pain |
RCT, randomized controlled trial; n-RCT, non-randomized controlled trial; CCT, controlled clinical trial; ACB, adductor canal block; FNB, femoral never block; TKA, total knee arthroplasty; A, pain; B, opioid consumption; C, hospital stay; D, complications; E, muscle strength; F, risk of falls; G, MVIC of Quadriceps and Adductor; H, time up & go test.
aTwo of these RCTs was not about TKA patients.
Figure 1Flow chart showing study identification, inclusion and exclusion.
Characteristics of the included randomized controlled trials.
| Author | Year | Country | Sample size | Age (mean) | Anaesthesia | Intervention | |||
|---|---|---|---|---|---|---|---|---|---|
| ACB | FNB | ACB | FNB | ACB | FNB | ||||
| Elkassabany | 2016 | USA | 31 | 31 | 63 | 65 | General/Spinal | 20 ml Ropivacaine 0.5% + LIF | 20 ml Ropivacaine 0.5% + LIF |
| Wiesmann | 2016 | Germany | 21 | 21 | 72 | 66 | General | Ropivacaine 0.2% + ASNB | Ropivacaine 0.2% + ASNB |
| Zhang | 2015 | China | 30 | 30 | 65 | 64 | General | 20 ml Ropivacaine 0.3% | 20 ml Ropivacaine 0.3% |
| Tan | 2015 | China | 40 | 40 | 65 | 63 | General | 20 ml Ropivacaine 5 g/L, 20 ml + 0.1 mg Epinephrine + LIF | 30 ml Ropivacaine 3.33 g/L + 0.1 mg Epinephrine + LIF |
| Memtsoudis | 2015 | USA | 30 | 29 | 64 | 64 | Spinal epidural | 15 ml bupivacaine 0.25% | 30 ml bupivacaine 0.25% |
| Machi | 2015 | USA | 39 | 41 | 67 | 66 | General/Spinal | Ropivacaine 0.2% | Ropivacaine 0.2% |
| Grevstad | 2015 | Denmark | 25 | 24 | 65 | 64 | Spinal | Ropivacaine 0.2% | Ropivacaine 0.2% |
| Zhang | 2014 | China | 30 | 30 | 64 | 62 | Spinal epidural | 20 ml Ropivacaine 0.33% | 20 ml Ropivacaine 0.33% |
| Shah | 2014 | India | 48 | 50 | 68 | 66 | Spinal | 20 ml Ropivacaine 0.75% + LIF | 30 cc. Ropivacaine 0.75% + LIF |
| Liu | 2014 | China | 19 | 19 | 61 | 63 | General | 20 ml Ropivacaine 0.5% + LIF | 30 ml Ropivacaine 0.33% + LIF |
| Kim | 2014 | USA | 46 | 47 | 68 | 68 | Spinal epidural | 15 cc Bupivacaine 0.5% + 5 μg/ml Epinephrine | 30 cc Bupivacaine 0.25% + 5 μg/ml Epinephrine |
| Jaeger | 2013 | Denmark | 22 | 26 | 70 | 66 | Spinal | 30 ml Ropivacaine 0.5% + 192 ml 0.2% Ropivacaine infusion | 30 ml Ropivacaine 0.5% + 192 ml 0.2% Ropivacaine infusion |
ASNB, anterior sciatic nerve block; ACB, adductor canal block; FNB, femoral never block; LIF, Local infiltration analgesia.
Figure 2(A) Risk of bias graph; (B) for Risk of bias summary (“+” indicates a low risk of bias, “−” indicates a high risk of bias, “?” indicates unclear or unknown risk of bias).
Figure 3Forest plot of quadriceps and adductor MVIC between ACB and FNB.
(MVIC, maximum voluntary isometric contraction).
Primary outcomes of meta-analyses in included randomized controlled trials.
| Variables | Studies | Patients (n) | Overall Effect | Heterogeneity P Value (I2) | Model | |
|---|---|---|---|---|---|---|
| P value | SMD/MD (95% CI) | |||||
| 2 h | 3 | 167 | 0.76 | 0.05 (−0.26, 0.35) | 0.95 (0%) | F |
| 4 h | 3 | 196 | 0.8 | −0.04 (−0.32, 0.24) | 0.14 (50%) | F |
| 6–8 h | 5 | 368 | 0.83 | 0.02 (−0.18, 0.23) | 0.09 (50%) | F |
| 12 h | 3 | 216 | 0.07 | −0.24 (−0.51, 0.02) | 0.59 (0%) | F |
| 24 h | 9 | 612 | 0.9 | −0.02 (−0.26, 0.23) | 0.02 (58%) | R |
| 24 h | 8 | 552 | 0.41 | 0.07 (−0.10, 0.24) | 0.29 (18%) | F |
| 48 h | 9 | 612 | 0.25 | −0.09 (−0.25, 0.06) | 0.70 (0%) | F |
| 72 h | 3 | 160 | 0.76 | −0.05 (−0.36, 0.26) | 0.33 (11%) | F |
| 2 h | 3 | 167 | 0.4 | 0.13 (−0.17, 0.44) | 0.18 (41%) | F |
| 4 h | 2 | 98 | 1 | 0.00 (−0.40, 0.40) | 1 (0%) | F |
| 6–8 h | 3 | 177 | 0.96 | −0.01 (−0.30, 0.29) | 0.67 (0%) | F |
| 12 h | 2 | 118 | 0.76 | −0.06 (−0.42, 0.30) | 0.38 (0%) | F |
| 24 h | 7 | 437 | 0.75 | −0.03 (−0.22, 0.16) | 0.24 (25%) | F |
| 48 h | 7 | 437 | 0.89 | −0.01 (−0.20, 0.17) | 0.42 (0%) | F |
| 72 h | 3 | 160 | 0.14 | 0.24 (−0.08, 0.55) | 0.24 (30%) | F |
| 2 h | 2 | 118 | 0.24 | 0.34 (−0.23, 0.90) | 0.14 (54%) | R |
| 4–6 h | 3 | 178 | 1.50 (0.70, 2.29) | 0.006 (81%) | R | |
| 4–6 h | 2 | 98 | < | 1.89 (1.40, 2.37) | 0.76 (0%) | F |
| 6–8 h | 2 | 97 | 0.08 | 0.36 (−0.04, 0.77) | 0.26 (22%) | F |
| 12 h | 2 | 118 | < | 0.87 (0.49, 1.25) | 0.20 (39%) | F |
| 24 h | 6 | 341 | < | 0.82 (0.45, 1.18) | 0.02 (62%) | R |
| 24 h | 4 | 202 | < | 1.09 (0.79, 1.39) | 0.55 (0%) | F |
| 48 h | 6 | 341 | < | 0.52 (0.13, 0.91) | 0.008 (68%) | R |
| 48 h | 4 | 241 | 0.63 (0.29, 0.97) | 0.28 (21%) | F | |
| 72 h | 3 | 160 | 0.91 (0.08, 1.74) | 0.003 (83%) | R | |
| 72 h | 2 | 80 | < | 1.32 (0.84, 1.81) | 1.00 (0%) | F |
| 2 | 97 | < | 1.55 (1.09, 2.01) | 0.39 (0%) | F | |
| 2 | 97 | 0.59 | −0.27 (−1.25, 0.72) | 0.02 (83%) | R | |
MVIC, maximum voluntary isometric contraction; SMD, standard mean differences; MD, mean differences; F, fixed-model effect; R, random-model effect.
*P values in bold denotes significance.
Figure 4Forest plot of pain score at rest between ACB and FNB.
Figure 5Forest plot of pain score at activity between ACB and FNB.
Secondary outcomes of meta-analyses in included randomized controlled trials.
| Variables | Studies (n) | Patients (n) | Overall Effect | Heterogeneity P Value (I2) | Model | |
|---|---|---|---|---|---|---|
| P value | MD/OR (95% CI) | |||||
| ROM | ||||||
| 24 h | 4 | 355 | < | 5.12 (2.80, 7.45) | 0.35 (9%) | F |
| 48 h | 4 | 257 | 8.39 (3.35, 13.44) | 0.08 (60%) | R | |
| 48 h | 3 | 197 | < | 11.10 (6.80, 15.40) | 0.84 (0%) | F |
| 72 h | 3 | 197 | < | 9.23 (6.45, 12.01) | 0.30 (8%) | F |
| Patients able to perform TUG test | ||||||
| <24 h | 3 | 226 | 23.14 (5.33, 100.37) | 0.91 (0%) | F | |
| 48 h | 2 | 121 | 0.58 | 1.19 (0.06, 24.85) | 0.06 (72%) | R |
| 72 h | 2 | 121 | 0.09 | 0.37 (0.12, 1.17) | 0.45 (0%) | F |
| Patients satisfaction | ||||||
| <24 h | 3 | 194 | 0.28 | 0.13 (−0.11, 0.37) | 0.77 (0%) | F |
| 48 h | 3 | 194 | 0.79 | −0.15 (−1.29, 0.98) | 0.02 (73%) | R |
| 72 h | 2 | 101 | 0.91 | 0.11 (−1.75, 1.97) | 0.02 (82%) | R |
| TUG test | 5 | 272 | 0.08 | −35.89 (−76.35, 4.58) | <0.0001 (98%) | R |
| TUG test | 4 | 174 | 0.09 | −12.19 (−26.47, 2.09) | 0.15 (44%) | F |
| The time to SLR | 3 | 195 | 0.13 | −2.19 (−5.02, 0.65) | 0.05 (75%) | R |
| Tourniquet time | 3 | 188 | 0.66 | −1.19 (−6.39, 4.02) | 0.62 (0%) | F |
| Hospital stay | 3 | 271 | 0.18 | −0.86 (−2.11, 0.40) | 0.02 (82%) | R |
| Opioid consumption | 5 | 332 | 0.62 | −2.93 (−14.47, 8.61) | 0.007 (72%) | R |
| Opioid consumption* | 4 | 283 | 0.39 | 2.56 (−3.24, 8.37) | 0.76 (0%) | F |
| Falls risk | 7 | 471 | 0.30 (0.13, 0.67) | 0.75 (0%) | F | |
| Nausea or vomiting | 4 | 309 | 0.98 | 1.01 (0.42, 2.45) | 0.88 (0%) | F |
| Pruritus | 3 | 221 | 0.69 | 1.15 (0.57, 2.32) | 0.94 (0%) | F |
| Urinary retention | 3 | 229 | 0.63 | 1.22 (0.54, 2.74) | 0.97 (0%) | F |
ROM, range of motion; SLR, straight leg raising; MD, mean differences; OR, odds ratio; F, fixed-model effect; R, random-model effect; TUG, timed-Up-and-Go.
*P values in bold denotes significance.
Figure 6(A) Forest plot of opioid consumption between ACB and FNB; (B) Forest plot of risk of falls between ACB and FNB.
Figure 7Funnel plots of primary outcomes.
(A) For pain score at rest; (B) for pain score at activity; (C) for quadriceps and adductor strength measured by MVIC; (D) for quadriceps strength measured by manual 5-grade motor-strength scale.